Showing 321 - 340 results of 362 for search '"Acadia"', query time: 0.18s Refine Results
  1. 321
  2. 322
  3. 323

    Property Risk Assessment of Sinkhole Hazard in Louisiana, U.S.A by Rubayet Bin Mostafiz, Carol J. Friedland, Robert V. Rohli, Robert V. Rohli, Nazla Bushra

    Published 2021-11-01
    “…Mary Parish—immediately west of Terrebonne—has the greatest risk of property loss. An Acadia Parish census tract has the maximum annual property losses in 2050 projected at $40,047 (2010$), and the highest projected annual per building ($43) and per capita ($18) property loss are in the same St. …”
    Get full text
    Article
  4. 324

    Analysis of Medicare Patients Treated with Pimavanserin versus Other Atypical Antipsychotics: A Cost-Offset Model Evaluating Skilled Nursing Facility Stays and Long-Term Care Admis... by Rajagopalan K, Rashid N, Yakkala V, Doshi D

    Published 2024-03-01
    “…Krithika Rajagopalan,1 Nazia Rashid,2 Vinod Yakkala,1 Dilesh Doshi2 1Anlitiks Inc., Windermere, FL, USA; 2Medical Affairs, Acadia Pharmaceuticals Inc., San Diego, CA, USACorrespondence: Krithika Rajagopalan, Anlitiks Inc., Email kr.rajagopalan@anlitiks.comBackground: Patients with Parkinson’s disease psychosis (PDP) treated with pimavanserin (PIM) versus other atypical antipsychotics (AAPs) including quetiapine (QUE) may have health-care cost savings due to fewer skilled nursing facility-stays (SNF-stays) and long-term care admissions (LTCA).Methods: A decision analytic model was developed using the 2019 Medicare Patient Driven Payment Model (PDPM) to estimate SNF-stays and LTCA associated per-patient- per-year (PPPY) facility and rehabilitation costs among patients that initiated PIM vs QUE or vs other-AAPs (i.e, quetiapine, risperidone, olanzapine, aripiprazole). …”
    Get full text
    Article
  5. 325
  6. 326
  7. 327
  8. 328
  9. 329
  10. 330
  11. 331
  12. 332
  13. 333

    Impact of Isolation During the COVID-19 Pandemic on the Patient Burden of Parkinson’s Disease: A PMD Alliance Survey by Hermanowicz N, Ospina MC, Torres-Yaghi Y, Gould S, Papesh K, Rivera JA, Miller S, Jones S, Musick K, May D

    Published 2022-03-01
    “…Vincent Neurology Specialists, Santa Fe, NM, USA; 2Regional Parkinson Center, Phoenix, AZ, USA; 3MedStar Georgetown University Hospital, Washington, DC, USA; 4Scripps Clinic Movement Disorder Center, La Jolla, CA, USA; 5Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA; 6Parkinson and Movement Disorder Alliance (PMD Alliance), Tucson, AZ, USA; 7ACADIA Pharmaceuticals Inc, San Diego, CA, USACorrespondence: Neal Hermanowicz, Tel +1 (505) 913-3877, Email nshermano@icloud.comPurpose: As the COVID-19 pandemic resulted in social restrictions around the globe, this cross-sectional survey aimed to assess the impact of social isolation on self- or proxy-reported symptoms of Parkinson’s disease (PD) during the pandemic.Patients and Methods: The survey was distributed among 7109 subscribers of the Parkinson and Movement Disorders Alliance (PMD Alliance) News and Information list and was open only to people with PD (PwP) and care partners (CP, defined as main caregivers of PwP and serving as proxy respondents). …”
    Get full text
    Article
  14. 334
  15. 335
  16. 336
  17. 337
  18. 338
  19. 339

    Standardized training in the rating of the six-item positive and negative syndrome scale (PANSS-6) by P. Kølbæk, D. Dines, J. Hansen, M. Opler, C. Correll, O. Mors, S. Østergaard

    Published 2021-04-01
    “…Correll has been a consultant and/or advisor to or have received honoraria from: Acadia, Alkermes, Allergan, Angelini, Axsome, Gedeon Richter, Gerson Lehrman Group, Indivior, IntraCellular T …”
    Get full text
    Article
  20. 340